Mega Matrix Announcesd That the Revenge Short Drama "The Returns of Billionaire Mom", Was First Released on August 29 at FlexTV

PALO ALTO, Calif. , Aug. 30, 2024 /PRNewswire/ -- Mega Matrix Corp. ("MPU" or the "Company") (NYSE American: MPU), today announced that it launched its revenge short drama "The Returns of Billionaire Mom" on August 29^th at FlexTV. This short drama is akin to a grand symphony, captivating audiences with its poignant narrative and profound emotions. It evokes deep reflections on female empowerment and self-redemption.

 

Harley once enjoyed boundless affection and glory, but due to the jealousy of her relatives and the betrayal of her lover, she lost everything. However, the dramatic turn of fate did not break her. With unwavering determination and a calm mind, she was reborn from the depths of despair and began plotting a secret revenge. Five years later, Harley returns with a new identity and a more resolute mindset. She is no longer the innocent young woman she once was but has transformed into a ruthless and decisive powerhouse. In facing those who once harmed her, every step of her revenge plan is meticulously crafted and executed with precision...

During the production of this short drama, the director and production team invested immense effort. They not only captured Harley's journey from despair to resilience with precision, but also infused the series with profound humanistic care and emotional depth. Every shot was meticulously crafted, and each plotline was carefully considered to authentically portray the resilience and wisdom of women in adversity. Meanwhile, the production team worked tirelessly behind the scenes, from planning to execution, striving for perfection in every detail to ensure an exceptional experience both visually and aurally.

MPU operates the world's leading short drama streaming platform FlexTV through Yuder Pte. Ltd., its indirect majority-controlled subsidiary, currently distributing short drama content to over 100 countries worldwide, covering multiple language versions such as English, Japanese, Korean, Portuguese, Spanish, French and Arabic. It has won the favor of audiences around the world with its high-quality short dramas and excellent user experience. "The Returns of Billionaire Mom" was released on FlexTV on August 29. This is not just a short drama centered on revenge but also a remarkable work showcasing female strength and wisdom. Through her resilience and composure, Harley gradually uncovers her adversaries' schemes and transforms past pain into the driving force for her progress, ultimately reclaiming everything that belongs to her. Her triumphant comeback reflects the essence of all women who, despite facing setbacks and challenges, never give up. For more exciting content, please visit https://www.flextv.cc/.

#Revenge# #Romance# #Short Drama# #FlexTV# #MPU#

About Mega Matrix: Mega Matrix Corp. (NYSE AMEX: MPU) is a holding company and operates FlexTV, a short-video streaming platform and producer of short dramas, through Yuder Pte, Ltd., an indirect majority-controlled subsidiary of Mega Matrix. Mega Matrix is a Delaware corporation headquartered in Palo Alto, CA. For more information, please contact info@megamatrix.io or visit: http://www.megamatrix.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements that are purely historical are forward looking statements. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose," and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees for future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the ability to manage growth; ability to identify and integrate future acquisitions; ability to grow and expand our FlexTV business; ability to execute the strategic cooperation with TopReels, ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting the Company's profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic; ; the possibility that the Company may not succeed in developing its new lines of businesses due to, among other things, changes in the business environment, competition, changes in regulation, or other economic and policy factors; and the possibility that the Company's new lines of business may be adversely affected by other economic, business, and/or competitive factors. The forward-looking statements in this press release and the Company's future results of operations are subject to additional risks and uncertainties set forth under the heading "Risk Factors" in documents filed by the Company with the Securities and Exchange Commission, including the Company's latest annual report on Form 10-K, and are based on information available to the Company on the date hereof. In addition, such risks and uncertainties include the Company's inability to predict or control bankruptcy proceedings and the uncertainties surrounding the ability to generate cash proceeds through the sale or other monetization of the Company's assets. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Disclosure Channels

We announce material information about the Company and its services and for complying with our disclosure obligation under Regulation FD via the following social media channels:

X (f/k/a Twitter): 

twitter.com/MegaMatrixMPU 

Facebook:

facebook.com/megamatrixmpu

facebook.com/flextvus

LinkedIn:

linkedin.com/company/megamatrixmpu

TikTok:

tiktok.com/@flextv_english

YouTube:

youtube.com/@FlexTV_English

The Company will also use its landing page on its corporate website (www.megamatrix.io) to host social media disclosures and/or links to/from such disclosures. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following our website, press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described above may be updated from time to time as listed on our website.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Mega Matrix Announcesd That the Revenge Short Drama "The Returns of Billionaire Mom", Was First Released on August 29 at FlexTV

Mega Matrix Announcesd That the Revenge Short Drama "The Returns of Billionaire Mom", Was First Released on August 29 at FlexTV

Mega Matrix Announcesd That the Revenge Short Drama "The Returns of Billionaire Mom", Was First Released on August 29 at FlexTV

Mega Matrix Announcesd That the Revenge Short Drama "The Returns of Billionaire Mom", Was First Released on August 29 at FlexTV

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.

The Breakthrough Therapy designation stems from the provisions of 《Food and Drug Administration Safety and Innovation Act》. It is designed to expedite the development and regulatory review of drugs for treating serious diseases and addressing significant unmet medical needs. The designation will be beneficial for the drugs to obtain the FDA's guidance in the clinical development, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected efficacy endpoints with a favorable safety profile. JAMA Neurology published the study's key findings online.

The designation will be beneficial for Simcere to obtain the FDA's guidance in the clinical development of Sanbexin sublingual tablets, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

According to a recent article in The Lancet, stroke is the second leading cause of death and disability worldwide, with 12 million new cases and 6.6 million deaths each year. Among them, acute ischemic stroke is the most common type of stroke, accounting for about 70% of all strokes, and constituting a heavy disease burden for all countries around the world. The efficacy of acute ischemic stroke treatment is highly time-dependent. Receiving treatment as early as possible will help patients to improve their disease outcome and avoid disability.

Sanbexin sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual formulation can quickly disintegrate once in contact with the saliva once place under the tongue and can be absorbed into the blood through the sublingual venous plexus, which is expected to increase the flexibility of stroke treatment. Sequential therapy consisting of the marketed Sanbexin concentrated solution for Injection. These two formulae enable patients to receive a complete course of treatment in and outside of the hospital.

On June 28, 2023, the new drug application (NDA) for Sanbexin sublingual tablets in China is accepted by the National Medical Products Administration. The first indication is for the improvement of neurological symptoms, daily activities, and functional impairment due to AIS. Phase I clinical trials for Sanbexin sublingual tablets on healthy volunteers have been completed in the United States.

CONTACT: Haoyun Huang, huanghaoyun@simcere.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration